Analytical Validation Strategy: Response (Calibration Model)

The webinar provides an in-depth understanding of the revised Q2 guideline, focusing on efficient validation for pharmaceutical product marketing authorization, ensuring adherence to future regulatory expectations.
  • Wednesday
  • September
  • 17
  • 2025
10:00 AM PDT | 01:00 PM EDT
Duration: 60 Minutes
IMG Joachim Ermer
Webinar Id: 61279
Live
Session
$119.00
Single Attendee
$249.00
Group Attendees
Recorded
Session
$159.00
Single Attendee
$359.00
Group Attendees
Combo
Live+Recorded
$249.00
Single Attendee
$549.00
Group Attendees

Overview:

Validation of analytical procedures, i.e. the demonstration of suitability for the intended purpose is an essential GMP and regulatory requirement. The new revision of the ICH guideline Q2(R2) “Analytical procedure validation” published end of 2023 provides recommendations to address the relevant performance characteristics. Some of the gaps and deficiencies of the old guideline have been addressed, for example the exclusive focus on chromatographic methods, new lifecycle aspects were considered (in combination with the new guideline Q14 “Analytical Procedure Development”), and some new requirements were adopted. However, its degree of detail is rather low, and the examples provided in Annex 2 often lack orientation beyond the guideline text, so that interpretation and orientation for a practically relevant validation design remains important.

Response is required for all (relative) quantitative analytical procedures (assay and impurities).

Why you should Attend:

A rational, efficient, and science-based validation is important to ensure an appropriate performance of analytical procedures as well as to obtain a marketing authorization of a pharmaceutical product. Therefore, a comprehensive understanding of the performance parameters is key. Participants will learn what aspects have changed and what is new in the revised Q2 guideline. A rational and efficient validation approach is ultimately based on the respective routine application, which should be reflected in the validation design as far as possible. 

The webinar will help participants to better understand the challenges, and thus to avoid pitfalls and be prepared for future regulatory expectations, leading to a targeted and efficient demonstration of suitability of the analytical procedure.

Areas Covered in the Session:

  • ICH Q2(R2): Range
  • Requirements to calibration models
  • ICH Q2(R2): Linear response 
  • Unweighted linear regression
  • Suitable regression parameters
  • Appropriate evaluation of the calibration model - residual plot
  • Weighted regression for large concentration ranges
  • Evaluation of the intercept
  • ICH Q2(R2): Non-linear response 

Who Will Benefit:

  • Analysts
  • lab supervisors and managers in Analytical Development and Quality Control responsible for method development, optimization, and validation
  • Quality Assurance and regulatory affairs representatives responsible to approve or evaluate analytical procedure validation

Speaker Profile

Dr. Joachim Ermer is a biochemist with 30 years of experience in pharmaceutical analytics, including development products at Hoechst AG, global responsibilities as Director of Analytical Processes and Technology at Aventis, and head of Quality Control and head of QC Lifecycle Management Frankfurt Chemistry at Sanofi. From 2010 till 2020, he was also responsible for the central reference standard group and Global Reference Standard Coordinator of Sanofi. Since December 2020, he serves as consultant for topics of pharmaceutical analytics and Quality Control. Joachim Ermer is member of the USP Expert Committee “Measurement and Data Quality“, of the Ph.Eur. Working Group “Chromatographic Separation Techniques”, and Advisory Board member of the ECA Analytical Quality Control Group.

He authored more than 60 publications on analytical topics and contributed to the USP General Information Chapter <1220> as well as other Stimuli Articles. He is editor and author of the book “Method Validation in Pharmaceutical Analysis. A Guide to Best Practice” (Wiley-VCH, 2005, 2015, 2024).